Zai Lab Ltd, publicly traded as ZLAB, is a leading global biopharmaceutical company primarily focused on discovering, developing, and commercializing innovative medicines for the treatment of various forms of cancer and autoimmune diseases. Established in 2014 and headquartered in Shanghai, China, the company has a diverse portfolio of marketed products and candidates at different stages of clinical research and development.
Zai Lab’s successful trajectory stems from its unwavering commitment to improving patient outcomes by addressing major healthcare concerns. This commitment is demonstrated in the company's robust pipeline of next-generation therapies, which include both small molecule and biologic therapies. Its rapid ascent in the biopharmaceutical sector is a testament to the company's cutting-edge research methodologies and ability to segment markets and formulate growth strategies.
The company's globally dispersed network of professionals integrates deep market insight, clinical development expertise, regulatory capabilities, business development, and robust intellectual property strategies to create accessible and affordable healthcare solutions. Zai Lab works diligently in collaboration with a global network of partners, which include multinational pharmaceutical giants, high-profile biotech companies, and academic institutions.
Zai Lab has thus made its mark on the biopharma sector with breakthroughs in oncology, autoimmune, and infectious diseases. Its focus on these fields is influenced by the urgency of unmet clinical needs and dedication to introducing highly-differentiated therapies that improve patient treatment options.
Some of the company's clinically advanced candidates target diseases such as breast cancer, gastric cancer, and lung cancer among others. Zai Lab’s marketed products are based on its licensed pharmaceutical technologies developed through strong partnerships with other pharmaceutical companies.
The company's culture encourages employees to remain ever curious, to keep exploring, and to never stray from their commitment to impact healthcare positively. Zai Lab embraces innovation as a company pillar and celebrates each breakthrough, no matter how small, acknowledging that all advancements collectively contribute to improving global healthcare standards.
In recent years, the company has witnessed a striking rise, which is reflected in its performance across global equity markets. As a publicly-traded company listed on the NASDAQ, ZLAB's stock performance is a strong testament to this upbeat market sentiment.
Zai Lab Ltd continues to make strides in accomplishing its ahead-of-the-curve mission of pushing the boundaries of medical innovation to create better and broader healthcare solutions for all.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Zai Lab's shares have surged after positive early Phase 1b data for its lung cancer candidate, zocilurtatug pelitecan (zoci), was presented at ESMO 2026, showing high response rates and a tolerable safety profile. Despite a long-term decline, the stock has seen significant short-term gains, trading at a discount to analyst targets and implied fair value. The company's future growth relies on successful product launches and pipeline execution in a competitive market, alongside managing geopolitical risks.
Zai Lab Limited has secured approximately $250 million through a private placement to fund the global development of its DLL3-targeting antibody-drug conjugate (ADC), zocilurtatug pelitecan (zoci). This financing, led by TCGX, will support the pivotal Phase III DLLEVATE trial for extensive-stage SCLC and preparation for a first-line global Phase III study by late 2026. The company recently reported promising Phase Ib data for zoci in combination with atezolizumab, showing an 81.8% objective response rate in first-line ES-SCLC patients.
Zai Lab (ZLAB) is gaining investor attention after announcing it will share ZL-1503 data at a November scientific meeting, following a year with a 33.81% YTD share price increase but a 19.31% one-year decline. The company is considered 30% undervalued by many, with a fair value around $33.30, driven by expected product launches and pipeline growth in China. However, a contrasting view suggests it looks expensive on sales, trading at 5.8x sales compared to a fair ratio of 3.3x, leading to debate over whether it represents a margin of safety or a valuation trap.
Zai Lab (ZLAB) is gaining investor attention after announcing it will share ZL-1503 data at a scientific meeting in November, following a 33.81% year-to-date share price increase despite a negative 1-year return. Analysts are divided, with some seeing the stock as 30% undervalued due to its strong pipeline and China footprint, projecting a fair value of $33.30, while others view it as expensive on sales at 5.8x compared to a fair ratio of 3.3x. Investors are encouraged to weigh both the potential upside and risks before making a decision.